Form 4: Blueprint Medicines CCO Philina Lee Reports Equity Transactions Following Sanofi Merger Completion

Blueprint Medicines' Chief Commercial Officer, Philina Lee, reported the conversion and disposition of her equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights following the company's acquisition by Sanofi.

Summary

• Philina Lee, Chief Commercial Officer of Blueprint Medicines Corp., reported transactions related to the company's merger with Sanofi's subsidiary.
• The merger, completed on July 17, 2025, involved a tender offer by Rothko Merger Sub, Inc., a wholly owned subsidiary of Aventis Inc. (a Sanofi subsidiary), to acquire all Blueprint Medicines common stock.
• Shareholders received $129.00 per share in cash and one contractual contingent value right (CVR) per share.
• Lee's performance-based vesting units (PSUs) and restricted stock units (RSUs) were cancelled and converted into the merger consideration.
• Outstanding stock options became fully vested, cancelled, and converted into the cash offer price (less exercise price) plus one CVR.
• A portion (50%) of PSUs, RSUs, and stock options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting, plus one CVR per underlying share.
• Lee's directly held common stock was tendered in exchange for the merger consideration.
• Following these transactions, Lee beneficially owns 0 shares of common stock and 0 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for shareholders and equity holders as the merger provides a significant cash payout and potential future value through CVRs, representing a successful exit for the company's public shareholders.

Positives

• Shareholders and equity holders, including the reporting person, received a cash payment of $129.00 per share.
• Equity awards (PSUs, RSUs, stock options) were converted into cash and contingent value rights (CVRs), providing liquidity and potential future payments.
• Stock options became fully vested upon the merger's effective time.

Negatives

• Blueprint Medicines Corp. ceased to be an independent publicly traded entity, becoming an indirect wholly owned subsidiary of Sanofi.

Risks

• The value of the contingent value rights (CVRs) is subject to the achievement of specific, undefined milestones, meaning the full 'Offer Consideration' is not guaranteed.

Future Outlook

The future outlook includes potential contingent payments from the Contingent Value Rights (CVRs) upon the achievement of certain milestones, as outlined in the Merger Agreement.

Industry Context

This filing reflects the completion of a significant acquisition in the pharmaceutical/biotechnology sector, where larger pharmaceutical companies like Sanofi often acquire smaller, innovative biotech firms like Blueprint Medicines to expand their pipeline and market presence. This is a common strategy for growth and diversification in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $129.00 cash per share plus one CVR, providing liquidity and potential future value.
• Employees (including Reporting Person): Equity awards (PSUs, RSUs, stock options) were converted into cash and CVRs, with some 2025 awards converting to cash-based awards subject to continued vesting, indicating retention incentives.
• Company (Blueprint Medicines): Ceased to be an independent public entity, becoming part of Sanofi's larger organization.

Next Steps

• Achievement of milestones for Contingent Value Rights (CVRs) to trigger potential future cash payments.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Form 4, Insider Trading, Equity Compensation, Stock Options, RSUs, PSUs, Contingent Value Rights, CVR, Tender Offer, Pharmaceutical, Biotechnology